A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function
Latest Information Update: 10 May 2022
At a glance
- Drugs Lobeglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 01 May 2022 Results published in the Clinical Pharmacology in Drug Development
- 08 Jul 2016 Status changed from recruiting to completed.
- 22 May 2014 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as reported by ClinicalTrials.gov.